Key facts
- It has raised $50.0M; the latest was Later Stage VC ($50.0M) in Dec 2025.
- Notable investors include CDP Venture Capital (Rome), Investissement Quebec, Genson Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Morphocell Technologies
- ·The full record, as it builds
Funding rounds
No funding rounds for Morphocell Technologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Morphocell Technologies
Operator of a regenerative medicine company intended to advance treatments using stem cell-based therapies. The company's cell therapy functions as an allogeneic solution that does not necessitate immunosuppression and can be extracted without lasting effects once liver function is restored through minimally invasive procedures, enabling medical professionals with an effective option for acute and chronic liver failure.
- Sector
- Healthcare
- HQ
- Laval, Canada
- Founded
- 2018
- Employees
- 44
- Website
- morphocell.com/
- Ownership
- Privately Held (backing)
Morphocell Technologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Morphocell Technologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Morphocell Technologies in its N-PORT filings yet. We sweep new filings monthly.